JL

Jeffrey V. Lazarus

Also known as: Jeffrey Victor Lazarus, Jeffrey V Lazarus, JV Lazarus

Barcelona Institute for Global Health, CUNY Graduate School of Public Health and Health Policy, University of Oxford, Lund University Samhällsvetenskapliga fakulteten

Research areas: Medicine · Hepatology · Liver Disease Diagnosis and Treatment · Hepatitis C virus research · HIV/AIDS Research and Interventions

ORCID iD 0000-0001-9618-2299
Follow

About

Jeffrey V. Lazarus (PhD, MIH, MA) is a professor of global health at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and holds positions as Research Professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, where he leads the Health Systems Research Group and was awarded the prestigious Miguel Servet grant, and as Associate Professor at the Faculty of Medicine, University of Barcelona.

From 2012 to 2019 he was an Affiliated Professor at CHIP, the WHO Collaborating Centre on HIV and Viral Hepatitis at Rigshospitalet, the University of Copenhagen, where he co-led two European Commission Joint Actions on infectious diseases (HA-REACT and INTEGRATE - as scientific director) and provided technical support to the Global Fund and WHO and its Member States. Since Feb 2023 he has been an affiliate professor of pharmaceutical policy at the WHO Collaborating Centre for research and training in the patient perspective on medicines use at the University of Copenhagen.

Dr Lazarus followed his decade-long (1998-2009) career as a health systems, HIV and viral hepatitis expert at WHO Europe with three years (2009-2012) as senior policy specialist at the Global Fund, then transitioned fully to the academic sector in 2012. He has had uninterrupted competitive funding since 2013. In 2015-16 he served as the first foreign Professor at the Lithuanian University of Health Sciences Medical Academy, from 2015-2018 as Board Chair of the foundation AFEW International and from 2016 to 2018 as editor in-chief of the journal Hepatology, Medicine and Policy.

After having served as a core member of The Lancet GastroHep Commission on Viral Hepatitis (2017-18), Dr Lazarus is is a working group chair of the EASL-Lancet European Liver Health Commission, on The Lancet COVID-19 Commission public health taskforce and chair of the HIV Fourth 90 Consensus Statement. He is the author of more than 200 publications, many in high-impact journals. He has presented at more than 75 conferences including the European Health Forum Gastein, the International AIDS Conference (IAS), the International Liver Congress (EASL), the Global Symposium on Health Systems Research (convened by Health Systems Global – where he was director from 2012 to 2015) and the International Conference for Integrated Care - and in 2020 co-chaired two Wilton Park policy thinktank events. His current scientific work includes serving as PI of COVID-SCORE, Hepatitis C Free Baleares, HBV COMSAVA, and the global NAFLD policy review as well as a work package leader of a European Commission project on integrated health services in sub-Saharan Africa. He currently supervises 4 PhD students and co-coordinates the Master of Global Health systems module at ISGlobal.

Dr Lazarus further serves as a Board Vice-Chair of the EASL International Liver Foundation, a member of the education committee of the International Network on Hepatitis among Substance Users (INHSU) and was co-convener of INHSU’s 7th International Symposium (Lisbon, 2018). In 2017, he was one of 18 recipients of The Economist Intelligence Unit Change Maker award, given in recognition of significant contributions to the global elimination of hepatitis C (http://pathtozero.eiu.com/).
PubMed/Medline: Lazarus JV; Scopus Author ID: 55431519100; Research Gate: Jeffrey V Lazarus; LinkedIN: Jeffrey V Lazarus Publons: https://publons.com/researcher/1654256/jeffrey-lazarus/ ResearcherID: R-6248-2018

Employment

Education

Projects & Funding

  • Mind The Liver Pfizer, S.A.
    2025 - 2027
  • Preventing and delaying the development if diabetes in Africa: a randomised placebo controlled double-blind phase lll trial of metformin in HIV-infected persons with prediabetes (The META Trial) European Commission
    2025 - 2026
  • A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM) European Commission
    2024 - 2030
  • An investment framework for action on steatotic liver disease (SLD): awareness and action on the cost of SLD (MASH Cost of Inaction Study - MASH-COST) Boehringer Ingelheim (Germany)
    2024 - 2024
  • Clinical Care Pathway Assessment Project, NAFLD/Diabetes (Proyecto CARPA) Novo Nordisk (Denmark)
    2023 - 2025
  • Boost access and quality of community-based communicable disease services for PWUD in the EU and neighboring countries (BOOST) European Commission
    2023 - 2025
  • Participatory and HIV Outcomes-Driven Experience Research (PODER) Pfizer Indendent Medical Education
    2023 - 2024
  • HCV COMmunity Screening And Linkage to care in Africans (HCV-COMSALA) Gilead Sciences Spain
    2022 - 2024
  • Multi-country Viral Hepatitis COMmunity, Screening, Vaccination and Care (VH-COMSAVAC) European Commission
    2022 - 2024
  • HIV Outcomes Beyond Viral Suppression: a Fourth 90 to improve the health of people living with HIV in Spain Fondo Investigaciones Sanitarias FIS
    2021 - 2023
  • A global cross-sectional survey of vaccine hesitancy and perceptions of COVID-19 vaccination programs (COVID-SCORE-VAC) MSD
    2021 - 2022
  • Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalisedpopulations in Spain AbbVie
    2021 - 2022
  • NASH Patient’s Itinerary: Comparison of strategies for screening, referring and management of diabetic patients (NASH-PI) Gilead Sciences
    2021 - 2023
  • SErvices for vulnerable MIgrants who use Drugs in the EU (SEMID-EU) European Commission
    2021 - 2023
  • COVID-VAC: COVID-19 vaccine hesitancy around the world revisited City University of New York
    2021 - 2022
  • HBV Care- Simplifying the HBV care pathway for Ghanaian and Senegalese migrants in Barcelona, Spain through community-based screening and vaccination, and linkage to care (HBV-COMSAVA) Gilead Sciences
    2020 - 2023
  • HCV Stat (The elimination of hepatitis C in the Balearic Islands, Spain) Gilead Sciences
    2020 - 2024
  • An Acceptability and Feasibility study of the Roche cobas® plasma separation card in a real-world setting in Tanzania and Uganda (AFROPLAS) Roche Molecular Systems, Inc
    2020 - 2023
  • Clinical study to evaluate the performance of two self-tests for the detection of antibodies against Hepatitis C virus (HCV) in the hands of untrained users Foundation for Innovative New Diagnostics (FIND)
    2020 - 2022
  • The micro-elimination of hepatitis C in Madrid European Commission
    2020 - 2020
  • EDCTP - Metformin HIV-Diabetes Trial European Commission
    2020 - 2024
  • Improving long-term health for people with HIV in Europe: development of a novel clinic screening tool and investigation of associations between HRQoL and health outcomes in two large longitudinal cohorts Gilead Sciences, S.L.
    2019 - 2023
  • A Pragmatic Approach to Improving Health-Related Quality of Life in People Living with HIV in Spain: Development of a Novel Clinic Screening Tool to Improve Clinical Management of Symptoms and Health-related Concerns (CST-HIV) Gilead Spain Fellowship
    2019 - 2020

Publications (609)